Henrik H Hansen

List of Publications by Year
in descending order

70 papers	4,024 citations	126907 33 h-index	123424 61 g-index
70 all docs	70 docs citations	70 times ranked	5493 citing authors

#	Article	IF	Citations
1	Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN dietâ€induced obese and biopsyâ€confirmed mouse model of NASH. Clinical and Translational Science, 2022, 15, 1167-1186.	3.1	26
2	Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease. Biomedicines, 2022, 10, 1661.	3.2	5
3	Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice. Biomedicine and Pharmacotherapy, 2021, 133, 110966.	5.6	12
4	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e966-e981.	3.6	22
5	Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice. Scientific Reports, 2021, 11, 8060.	3.3	6
6	Whole-brain activation signatures of weight-lowering drugs. Molecular Metabolism, 2021, 47, 101171.	6.5	25
7	Wholeâ€brain mapping of amylinâ€induced neuronal activity in receptor activityâ€“modifying protein 1/3 knockout mice. European Journal of Neuroscience, 2021, 54, 4154-4166.	2.6	8
8	Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. American Journal of Physiology - Renal Physiology, 2021, 321, F149-F161.	2.7	16
9	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterology, 2020, 20, 210.	2.0	47
10	Whole-brain three-dimensional imaging for quantification of drug targets and treatment effects in mouse models of neurodegenerative diseases. Neural Regeneration Research, 2020, 15, 2255.	3.0	3
11	Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Scientific Reports, 2019, 9, 15582.	3.3	64
12	Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Scientific Reports, 2019, 9, 9046.	3.3	35
13	Animal Models of Type 2 Diabetes, Obesity and Nonalcoholic SteatohepatitisÂâ€“ Clinical Translatability and Applicability in Preclinical Drug Development. , 2019, , 369-403.		4
14	Global transcriptome analysis of rat hypothalamic arcuate nucleus demonstrates reversal of hypothalamic gliosis following surgically and diet induced weight loss. Scientific Reports, 2019, 9, 16161.	3.3	7
15	Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice. Biomedicine and Pharmacotherapy, 2019, 109, 167-173.	5.6	10
16	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. American Journal of Physiology - Renal Physiology, 2019, 316, G462-G472.	3.4	162
17	Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 2019, 64, 1238-1256.	2.3	15
18	Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World Journal of Gastroenterology, 2019, 25, 4904-4920.	3.3	75

#	Article	IF	Citations
19	Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control. Peptides, 2018, 101, 32-43.	2.4	15
20	Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2018, 24, 179-194.	3.3	105
21	INT-767 improves histopathological features in a diet-induced<i>ob/ob</i>mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2018, 24, 195-210.	3.3	57
22	Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today, 2017, 22, 1707-1718.	6.4	178
23	Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease. Frontiers in Neuroanatomy, 2017, 11, 109.	1.7	8
24	Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on Î²-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimerâ€™s Disease. PLoS ONE, 2016, 11, e0158205.	2.5	39
25	Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. Brain Research, 2016, 1646, 354-365.	2.2	34
26	Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass. Molecular Metabolism, 2016, 5, 296-304.	6.5	24
27	Changes in Binding of [123I]CLINDE, a High-Affinity Translocator Protein 18ÂkDa (TSPO) Selective Radioligand in a Rat Model of Traumatic Brain Injury. NeuroMolecular Medicine, 2016, 18, 158-169.	3.4	18
28	The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Research, 2016, 1634, 158-170.	2.2	67
29	The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 877-888.	2.6	128
30	The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves <i>Î²</i>-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 657-664.	2.5	53
31	The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat. European Journal of Pharmacology, 2014, 741, 254-263.	3.5	36
32	Acute Phencyclidine Treatment Induces Extensive and Distinct Protein Phosphorylation in Rat Frontal Cortex. Journal of Proteome Research, 2014, 13, 1578-1592.	3.7	13
33	Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology Biochemistry and Behavior, 2013, 110, 265-271.	2.9	27
34	Antiâ€hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity, 2013, 21, 985-992.	3.0	19
35	The Î±4Î²2 nicotine acetylcholine receptor agonist ispronicline induces c-Fos expression in selective regions of the rat forebrain. Neuroscience Letters, 2012, 515, 7-11.	2.1	1
36	Epigenetic regulation of Arc and c-Fos in the hippocampus after acute electroconvulsive stimulation in the rat. Brain Research Bulletin, 2012, 88, 507-513.	3.0	37

#	Article	IF	Citations
37	K_v7 (KCNQ) channel openers normalize central 2â€deoxyglucose uptake in a mouse model of mania and increase prefrontal cortical and hippocampal serineâ€9 phosphorylation levels of GSK3Î². Journal of Neurochemistry, 2012, 121, 373-382.	3.9	19
38	Kv7 (KCNQ) channel openers induce hypothermia in the mouse. Neuroscience Letters, 2011, 488, 178-182.	2.1	16
39	The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. European Journal of Pharmacology, 2010, 636, 88-95.	3.5	31
40	Use of biomarkers in the discovery of novel anti-schizophrenia drugs. Drug Discovery Today, 2010, 15, 137-141.	6.4	10
41	Repeated administration of Î±7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases Î±7 nAChR levels in the brain. Journal of Neurochemistry, 2010, 114, 1205-1216.	3.9	34
42	Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of Î±1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat. Neuropsychopharmacology, 2010, 35, 1464-1476.	5.4	44
43	Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology. Current Pharmaceutical Design, 2010, 16, 323-343.	1.9	182
44	Opposite effect of phencyclidine on activity-regulated cytoskeleton-associated protein (Arc) in juvenile and adult limbic rat brain regions. Neurochemistry International, 2010, 56, 270-275.	3.8	16
45	Î±7 Nicotinic receptor agonism mitigates phencyclidine-induced changes in synaptophysin and Arc gene expression in the mouse prefrontal cortex. Neurochemistry International, 2010, 57, 756-761.	3.8	7
46	Î±7 Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology, 2009, 56, 1001-1009.	4.1	73
47	Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. Journal of Neurochemistry, 2008, 76, 39-46.	3.9	89
48	GABA Regulates the Rat Hypothalamicâ€Pituitaryâ€Adrenocortical Axis via Different GABAâ€A Receptor Î±â€Subtypes. Annals of the New York Academy of Sciences, 2008, 1148, 384-392.	3.8	20
49	Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS. Journal of Physiology, 2008, 586, 1823-1832.	2.9	73
50	Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nature Neuroscience, 2008, 11, 476-487.	14.8	483
51	The nicotinic Î±7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-Î²1â€“42. Brain Research, 2008, 1227, 240-247.	2.2	23
52	The Î±7 nicotinic receptor agonist SSR180711 increases activity regulated cytoskeleton protein (Arc) gene expression in the prefrontal cortex of the rat. Neuroscience Letters, 2007, 418, 154-158.	2.1	29
53	Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: An effect similar to antipsychotics. Journal of Neuroscience Research, 2007, 85, 1810-1818.	2.9	37
54	Rapid Activation of the Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Signaling Pathway by Electroconvulsive Shock in the Rat Prefrontal Cortex Is Not Associated with TrkB Neurotrophin Receptor Activation. Cellular and Molecular Neurobiology, 2007, 27, 585-594.	3.3	17

#	Article	IF	Citations
55	Kv7 Channels: Function, Pharmacology and Channel Modulators. Current Topics in Medicinal Chemistry, 2006, 6, 999-1023.	2.1	55
56	The KCNQ Channel Opener Retigabine Inhibits the Activity of Mesencephalic Dopaminergic Systems of the Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1006-1019.	2.5	67
57	NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15605-15610.	7.1	129
58	Erythropoietin protects the developing brain against N-methyl-d-aspartate receptor antagonist neurotoxicity. Neurobiology of Disease, 2004, 15, 177-187.	4.4	135
59	Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiology of Disease, 2004, 16, 440-453.	4.4	149
60	Neuropathological and biochemical features of traumatic injury in the developing brain. Neurotoxicity Research, 2003, 5, 475-490.	2.7	31
61	Brain levels of N-acylethanolamine phospholipids in mice during pentylenetetrazol-induced seizure. Lipids, 2003, 38, 387-390.	1.7	22
62	Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases. Neurotoxicity Research, 2003, 5, 183-199.	2.7	19
63	Determination of the Phospholipid Precursor of Anandamide and Other N-Acylethanolamine Phospholipids Before and After Sodium Azide-Induced Toxicity in Cultured Neocortical Neurons. Journal of Neurochemistry, 2002, 75, 861-871.	3.9	55
64	Blockade of cannabinoid CB₁ receptor function protects against <i>inâ€ƒvivo</i> disseminating brain damage following NMDAâ€induced excitotoxicity. Journal of Neurochemistry, 2002, 82, 154-158.	3.9	76
65	Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse, 2002, 44, 23-35.	1.2	114
66	Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. Journal of Neurochemistry, 2001, 78, 1415-1427.	3.9	197
67	Effects of cannabinoids on adrenaline release from adrenal medullary cells. British Journal of Pharmacology, 2001, 134, 1319-1327.	5.4	44
68	N-Acylethanolamines and precursor phospholipids â€” relation to cell injury. Chemistry and Physics of Lipids, 2000, 108, 135-150.	3.2	214
69	Electrospray ionization mass spectrometric method for the determination of cannabinoid precursors:N-acylethanolamine phospholipids (NAPEs). Journal of Mass Spectrometry, 1999, 34, 761-767.	1.6	27
70	Formation of N-Acyl-phosphatidylethanolamines and N-Acylethanolamines. Biochemical Pharmacology, 1998, 55, 719-725.	4.4	86